GCP
ACRV icon

GSA Capital Partners’s Acrivon Therapeutics ACRV Stock Holding History

GSA Capital Partners’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Buy
200,415
+13,699
+7% +$23.3K 0.02% 1210
2026
Q1 		$260K Buy
+186,716
New +$326K 0.02% 1327

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's ACRV Position: Q2 2026 in Review

GSA Capital Partners increased its Acrivon Therapeutics (ACRV) stake by 7.3% in Q2 2026, buying an estimated $23.3K and bringing the position to 200,415 shares worth $357K. The position accounts for 0.02% of the portfolio, ranked #1210.

GSA Capital Partners first reported a position in ACRV in Q1 2026 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • GSA Capital Partners held 200,415 shares of Acrivon Therapeutics worth $357K as of Q2 2026.
  • GSA Capital Partners bought 13,699 Acrivon Therapeutics shares in Q2 2026, an estimated $23.3K.
  • Acrivon Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1210 holding.
  • GSA Capital Partners first reported a position in Acrivon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.